A prospective phase II study to evaluate olaparib plus abiraterone and prednisone combination therapy in metastatic hormone sensitive prostate cancer patients with HRR gene mutation: Updated analysis of PROact.

Authors: Junlong Zhuang, Shun Zhang, Xuyu Zhang, Xuefeng Qiu, Xi Zheng, Jie Gao, Hongqian Guo

Published: 2025-02-18

DOI: 10.1200/jco.2025.43.5_suppl.tps292

Source: Full article

TPS292